Analysts See 30% Gains Ahead For The Holdings of XBI

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $83.80 per unit.

START SLIDESHOW:
10 ETFs With Most Upside To Analyst Targets »

With XBI trading at a recent price near $64.35 per unit, that means that analysts see 30.23% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of XBI's underlying holdings with notable upside to their analyst target prices are Sangamo BioSciences Inc ( SGMO), ZIOPHARM Oncology Inc ( ZIOP), and Geron Corp. ( GERN). Although SGMO has traded at a recent price of $3.25/share, the average analyst target is 176.92% higher at $9.00/share. Similarly, ZIOP has 105.58% upside from the recent share price of $6.81 if the average analyst target price of $14.00/share is reached, and analysts on average are expecting GERN to reach a target price of $4.17/share, which is 96.51% above the recent price of $2.12. Below is a twelve month price history chart comparing the stock performance of SGMO, ZIOP, and GERN:

SGMO, ZIOP, and GERN Relative Performance Chart

Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
SPDR S&P Biotech ETF XBI $64.35 $83.80 30.23%
Sangamo BioSciences Inc SGMO $3.25 $9.00 176.92%
ZIOPHARM Oncology Inc ZIOP $6.81 $14.00 105.58%
Geron Corp. GERN $2.12 $4.17 96.51%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

More from Stocks

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

This Should Be Your Retirement Savings Plan When the Stock Market Crashes

This Should Be Your Retirement Savings Plan When the Stock Market Crashes